CA3164938A1 - Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections - Google Patents

Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections

Info

Publication number
CA3164938A1
CA3164938A1 CA3164938A CA3164938A CA3164938A1 CA 3164938 A1 CA3164938 A1 CA 3164938A1 CA 3164938 A CA3164938 A CA 3164938A CA 3164938 A CA3164938 A CA 3164938A CA 3164938 A1 CA3164938 A1 CA 3164938A1
Authority
CA
Canada
Prior art keywords
substituted
oxy
pharmaceutically acceptable
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3164938A
Other languages
English (en)
French (fr)
Inventor
Joaquim Trias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arixa Pharmaceuticals Inc
Original Assignee
Arixa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arixa Pharmaceuticals Inc filed Critical Arixa Pharmaceuticals Inc
Publication of CA3164938A1 publication Critical patent/CA3164938A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3164938A 2019-12-20 2020-12-17 Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections Pending CA3164938A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951187P 2019-12-20 2019-12-20
US62/951,187 2019-12-20
PCT/IB2020/062099 WO2021124191A1 (en) 2019-12-20 2020-12-17 Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections

Publications (1)

Publication Number Publication Date
CA3164938A1 true CA3164938A1 (en) 2021-06-24

Family

ID=73856245

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3164938A Pending CA3164938A1 (en) 2019-12-20 2020-12-17 Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections

Country Status (8)

Country Link
US (2) US20210186983A1 (https=)
EP (1) EP4076451A1 (https=)
JP (2) JP2021102605A (https=)
KR (1) KR20220114629A (https=)
CN (1) CN115003302A (https=)
AU (1) AU2020405540A1 (https=)
CA (1) CA3164938A1 (https=)
WO (1) WO2021124191A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119841826B (zh) * 2024-09-30 2026-04-10 科睿迪(南京)医药科技有限公司 二氮杂二环类β-内酰胺酶抑制剂及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
JP2022524118A (ja) * 2019-03-12 2022-04-27 アリクサ ファーマシューティカルズ、インコーポレイテッド アビバクタム誘導体の結晶形

Also Published As

Publication number Publication date
US20240245705A1 (en) 2024-07-25
EP4076451A1 (en) 2022-10-26
WO2021124191A1 (en) 2021-06-24
US20210186983A1 (en) 2021-06-24
AU2020405540A1 (en) 2022-06-09
CN115003302A (zh) 2022-09-02
KR20220114629A (ko) 2022-08-17
JP2021102605A (ja) 2021-07-15
JP2025163188A (ja) 2025-10-28

Similar Documents

Publication Publication Date Title
AU2024201877B2 (en) Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections
AU2020227077B2 (en) Beta-lactamase inhibitors and uses thereof
US11008321B2 (en) Crystalline form of an avibactam derivative
JP2025163188A (ja) マイコバクテリア感染症を治療するための、アモキシシリン誘導体とアビバクタム誘導体の組み合わせ経口投与
EP3860999B1 (en) Derivatives of relebactam and uses thereof
HK40083209A (en) Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections
RU2825281C1 (ru) Вводимые перорально комбинации бета-лактамных антибиотиков и производных авибактама для лечения бактериальных инфекций
HK40072825A (en) Orally administered combinations of beta lactam antibiotics and avibactam derivatives for treating bacterial infections
HK40063686A (en) Crystalline form of an avibactam derivative
RU2815314C2 (ru) Ингибиторы бета-лактамаз и их применение
NZ758795B2 (en) Atropine pharmaceutical compositions
NZ758795A (en) Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220615

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128